Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687934 | 0.83 | PARP1 (1.00) | PARP1HTR3A | |
| SCHEMBL742407 | 0.83 | PARP1 (1.00) | PARP1HTR3A | |
| SCHEMBL12750325 | 0.81 | PARP1 (0.69) | PARP1CA12CA9AURKAKDR | |
| SCHEMBL13475834 | 0.79 | PARP1 (0.65) | PARP1CA12CA9AURKAKDR | |
| Phosphoric Acid SCHEMBL29456911 | 0.77 | PARP1 (0.86) | PARP1HTR3A | |
| SCHEMBL22300798 | 0.76 | PARP1 (0.60) | PARP1HTR3AKDM4EMEN1USP2 | |
| SCHEMBL261487 | 0.74 | PARP1 (0.64) | PARP1HTR3AKDM4EMEN1USP2 | |
| SCHEMBL29688203 | 0.73 | PARP1 (1.00) | PARP1CA12CA9AURKAKDR | |
| SCHEMBL832168 | 0.73 | PARP1 (1.00) | PARP1CA12CA9AURKAKDR | |
| SCHEMBL11242694 | 0.71 | PARP1 (0.60) | PARP1HTR3AKDM4EMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | claimed |
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| EP-2134714-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | Biovitrum AB (publ) (SE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
| WO-2008110598-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | BIOVITRUM AB (PUBL) (SE) | 2008-09-18 | — | — | WO | disclosed |
| EP-1140936-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMA (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030078254-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | WEBBER STEPHEN EVAN (US) | 2003-04-24 | — | — | US | disclosed |
| US-6495541-B1 | POTENTIATION OF ANTICANCER THERAPIES AND INHIBITION OF NEUROTOXICITY CONSEQUENT TO STROKE, HEAD TRAUMA, AND NEURO-DEGENERATIVE DISEASES; SUCH AS 2-BROMO-3,4-DIHYDROPYRROLO-(4,3,2-DE)ISOGUINOLIN-5-ONE | AGOURON PHARMACEUTICALS, INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020160984-A1 | Fused tricyclic compounds, methods and compositions for inhibiting parp activity | GUILFORD PHARMACEUTICALS INC. | 2002-10-31 | — | — | US | disclosed |
| US-6380193-B1 | POLY(ADENOSINE 5'-DIPHOSPHO-RIBOSE)POLYMERASE; TREATMENT OR PREVENTION OF NEUROLOGICAL AND NEURODEGENERATIVE DISEASES, VASCULAR STROKE | GUILFORD PHARMACEUTICALS INC. | 2002-04-30 | — | — | US | disclosed |
| US-6121278-A | POLY(ADENOSINE 5'-DIPHOSPHO-RIBOSE)POLYMERASE (PARP) ENZYME INHIBITOR FOR TREATMENT OF NEUROLOGICAL DISORDERS, ARTHRITIS, DIABETES, INFLAMMATION, CARDIOVASCULAR DISORDERS, SEPTIC SHOCK, CANCER | GUILFORD PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-3978066-A | Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives | AYERST, MCKENNA AND HARRISON LTD. (CA) | 1976-08-31 | — | — | US | disclosed |
| US-3950343-A | PYRROLOISOQUINOLINE DERIVATIVES | AYERST, MCKENNA AND HARRISON LTD. (CA) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293694-A1 | New compounds | HTR6, HTR1A, HTR1B | PARP1 2147/4885CA12 4734/4885CA9 4802/4885 |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | PARP1, PARP2, PARP12 | PARP1 1/4885CA12 3158/4885CA9 2950/4885 |
| US-20030078254-A1 | Tricyclic inhibitors of poly(ADP-ribose) polymerases | PARP1, PARP11, PARP2 | PARP1 1/4885CA12 4114/4885CA9 2909/4885 |
| US-20020160984-A1 | Fused tricyclic compounds, methods and compositions for inhibiting parp activity | PARP4, PARP1, PARP6 | PARP1 2/4885CA12 3940/4885CA9 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.